Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 91 AL 105

Reframing Alzheimer's Disease Through a Redox-Metabolic Framework

Velázquez De Castro-Bono A, Castro-Luna G, Guil-Guerrero JL.

Int J Mol Sci. 2026 Sep 17;27(18):8294. doi: 10.3390/ijms27188294.

Pharmacotherapy for Alzheimer's Disease and Dementias in Long-Term Care: A Real-World EHR Study

Saumur TM, Ashraf H, Mathers KE, Wagner B.

J Am Med Dir Assoc. 2026 Sep;27(9):106293. doi: 10.1016/j.jamda.2026.106293. Epub 2026 Jul 3.

Nanomedicine targeting neuroinflammatory pathways in Alzheimer's disease: a new frontier in inflammopharmacology

Kaushik S, Fatima JE, Raheem A, Barbhuiya MA, Thirupathi AT, Singh LP, Khan PA, Aparna TN, Pramanik S, Shahid MAA.

Inflammopharmacology. 2026 Aug;34(8):5365-5404. doi: 10.1007/s10787-026-02329-9. Epub 2026 Jul 17.

Rational drug design for Alzheimer's disease: from approved therapies to next-generation clinical candidates and AI-guided innovation

Saffour S, Gul TS, Gul HI.

Future Med Chem. 2026 Sep;18(17):2425-2443. doi: 10.1080/17568919.2026.2714022. Epub 2026 Aug 10.

Human Stem Cell-Derived Models of the Alzheimer's Disease Neuroimmune System

Summers RA, Quang D, Johnson NR.

Int J Mol Sci. 2026 Aug 18;27(16):7360. doi: 10.3390/ijms27167360.

Caenorhabditis elegans as a Model for Studying Nrf2/SKN-1 Activation in Alzheimer's Disease: Plant Bioactive Compounds and Therapeutic Translation

Bellver-Sanchis A, Ralchev NR, Romanska PR, Dyakova NK, Ivanova KI, Griñán-Ferré C, Marchev AS.

Int J Mol Sci. 2026 Sep 1;27(17):7833. doi: 10.3390/ijms27177833.

Unlocking the Potential of Isatin Scaffolds in Acetylcholinesterase Inhibition

Tharwat T, El-Nassan HB, Adly ME, Kamel MM.

Arch Pharm (Weinheim). 2026 Sep;359(9):e70336. doi: 10.1002/ardp.70336.

Enhancing brain delivery of tegaserod for Alzheimer's disease: a pharmaceutical comparison of two nanocarrier-based strategies

Séguy L, Guyon L, Corvaisier S, Maurel M, Verdié P, Herbinet R, Pluart LL, Dehouck L, Sevin E, Fenart L, Gosselet F, Lagadu S, Née G, Fréret T, Since M, Delépée R, Dallemagne P, Lisowski V, Groo AC, Malzert-Fréon A.

Int J Pharm. 2026 Sep 5;702:127181. doi: 10.1016/j.ijpharm.2026.127181. Epub 2026 Jul 15.

Putative Modulation of OATP1A2 and P-gp Expression at the Blood-Brain Barrier by Nrf2-PXR: An Associative Hypothesis for Amyloid-β Transport in Alzheimer's Disease

Li L, Zhang Y, Li S, Zhao M, Hu W, Xiao Y, Wen J.

Int J Mol Sci. 2026 Aug 14;27(16):7264. doi: 10.3390/ijms27167264.

Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions

Zupan M, Prelog PR, Kramberger MG, Frol S.

Front Neurol. 2026 Aug 19;17:1889769. doi: 10.3389/fneur.2026.1889769. eCollection 2026.

Biochemical modulators of synaptic plasticity: New horizons in Alzheimer's disease treatment

Farzeen I, Nazir MM, Jaan Z, Ghaffar W, Masood A, Yasmeen M, Ashraf A, Różański H.

J Alzheimers Dis. 2026 Sep;113(2):501-518. doi: 10.1177/13872877261469864. Epub 2026 Jul 23.

Irisin-BDNF axis mediates muscle-brain communication: a complete molecular cascade and potential bidirectional feedback from peripheral activation to central protection

Duan X, Chen Z, Tong X, Li X, Liu Z, Yang Y, Liu X, Liu W.

Biogerontology. 2026 Sep 19;27(5):162. doi: 10.1007/s10522-026-10510-4.

Neuroinflammatory and molecular pathways in Alzheimer's disease: mechanistic crosstalk and emerging therapeutic opportunities

Thakur A, Sharma R, Kumari S, Prakash D, Devi A.

Inflammopharmacology. 2026 Sep;34(9):6059-6088. doi: 10.1007/s10787-026-02371-7. Epub 2026 Aug 19.

Targeting microglia: A new strategy for the treatment of Alzheimer's disease

Zheng M, Yang M, Su W, Tian L, Gao W.

J Neuroimmunol. 2026 Sep;418:578966. doi: 10.1016/j.jneuroim.2026.578966. Epub 2026 May 14.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias